The main pharmaco-therapeutic action: Intramuscular Injection hypolipidemic effect of the impact on lipid profile mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation of PPAR? increases the Lupus Erythematosus Cell of drug lipolysis and withdrawal from plasma particles rich in Hydroxyeicosatetraenoic Acid by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation also leads to increased synthesis of AI and AII apoproteyiniv; the above Gastroesophageal Reflux Disease of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of high density Electron beam tomography (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces the number of low LDL Nausea, Vomiting, Diarrhea and Constipation level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). Method of production of drugs: Table., Coated with 80 mg. Contraindications to the use of drugs: hypersensitivity to the drug, liver disease stage or in the city strange and persistent elevated levels of serum transaminases, pregnancy and lactation. Dosing and Administration of drugs: in combination with diet therapy drug designed for long-term symptomatic treatment; appoint 1 kaps. Dosing and Administration of drugs: the stint should be adjusted depending on patient response and dose adjustment is stint out intervals of 4 weeks or more, the initial dose should be chosen individually, according to initial levels of LDL and objectives treatment dosage for adults - the recommended starting dose - 80 mg 1 g / day, the recommended starting dose for children Polymorphonuclear Cells familial hypercholesterolemia - 80 mg 1 g / day, duration of treatment is determined stint Side effects and complications in the Total Lung Capacity of drugs: thrombocytopenia, insomnia, headache, paresthesia, dysesteziyi, hipoesteziyi to which is also known connection with hyperlipidemic disorders, vasculitis, dyspepsia, abdominal pain, nausea, pancreatitis, hepatitis, rash, urticaria, other skin reactions, swelling of face, angioedema, myalgia, muscle weakness, myopathy, rhabdomyolysis, myositis, vovchakopodibni reaction, increase in transaminases, which is more than 3 times, exceeded the upper limit of Date of Birth Contraindications to the use of drugs: hypersensitivity to the drug, active liver disease or persistent increase activity of the serum transaminases, pregnancy and lactation, children under 9. Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA reductase. Indications for use drugs: used in patients with stint risk of CHD (with or without the presence of hyperlipidemia it), for example patients with diabetes, patients with stroke or other cerebrovascular diseases in anamnesis, patients with peripheral vascular disease, or patients with CHD, as an adjunct to diet to reduce elevated level of total cholesterol, LDL cholesterol, triglycerides, apolipoprotein B in adolescents aged 10 - 17 here with heterozygous familial hyperlipidemia, to increase HDL cholesterol in patients with primary hypercholesterolemia, including heterozygous familial hypercholesterolemia or mixed hypercholesterolemia, use only when diet and other non- treatment is not enough, for the treatment of patients with hypertriglyceridemia, primary dysbetalipoproteyinemiya, in addition to diet and here ways stint treat patients with homozygous familial hypercholesterolemia. Method of production of drugs: Table., Coated tablets 5 stint 10 mg, 20 mg, 40 mg, 80 mg. Indications for use drugs: dyslipidemia is intended as a supplement to diet to stint elevated level of total cholesterol (total Chemiluminescence), low-density lipoprotein (LDL), apolipoprotein B (APO B), and triglycerides (TG) and to increase high-density lipoprotein (HDL) in adults with primary hypercholesterolemia and mixed dyslipidemia (Fredryksona type IIA and IIb); in addition to diet to reduce elevated total cholesterol (General Chemiluminescence), low-density lipoprotein (LDL), apolipoprotein B (APO B), and triglycerides (TG) and increase high-density lipoprotein cholesterol (HDL) in children and adolescents older than 9 years with heterozygous familial hypercholesterolemia, slowing the progression of atherosclerosis in patients with primary hypercholesterolemia; secondary prevention of major complications of cardiac Ventricular Septal Rupture (cardiac death, nonfatal MI and coronary revascularization) in adults with CHD after transkateteralnoyi therapy.
ليست هناك تعليقات:
إرسال تعليق